It is also known that antibodies are an immune component highly significant to the clinical outcome severity of encephalitic alphavirus infections, though the neutralisation dynamics and efficacy are not fully understood in encephalitic alphaviruses, posing barriers to therapeutic monoclonal antibody (mAb) administration [ 75 ]. 4.7.
← all excerpts
Encephalitic Alphaviruses: Epidemiology, Pathogenesis and Vaccine Development.
1
—
—